Drug Drug Interaction
What is the DDI Module?
The DDI Module in GastroPlus® allows you to predict mechanistic and static drug-drug interactions (DDIs) among drugs and metabolites. The ability to accurately estimate potential DDIs in silico has several benefits for pharmaceutical companies:
- Explore possible effects on the pharmacology and toxicology of drugs
- Identify species-specific changes to estimate how a drug behaves in animals vs. humans
- Investigate the safety profile of drugs that are co-administered prior to filing regulatory submissions with the FDA, EMA, and other agencies
Resources
-
Prediction of Omeprazole’s Disposition and Drug-Drug Interactions Using A Physiologically-Based Pharmacokinetic Model
DownloadDownload the poster presented at the ADMET Europe 2010 conference on the development of PBPK models and prediction of parent & metabolite DDIs with omeprazole.
-
Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-drug Interactions (DDIs)
DownloadDownload the poster presented at the Rosenon conference in 2009 on the development of PBPK models for common azole antifungals and DDI predictions
-
Mechanistic Absorption and Physiologically Based Pharmacokinetic Modeling of Itraconazole and Its Application for Drug-Drug Interaction with Midazolam in Adult Populations
Learn MoreItraconazole (ITZ) is a BCS Class II triazole antifungal (Sporanox; Janssen Pharmaceutica, Titusville, NJ). It is a substrate and potent inhibitor of CYP3A4. The primary metabolite hydroxy-itraconazole...
